Currently, tumor biopsies are the most commonly used diagnostic tool for lung cancer. However, this article talks about the huge potential of liquid biopsies obtained from a blood sample to replace tumor biopsies that require patients to undergo surgery.
With Dr Rao, the article was co-published with a team from the Markey Cancer Center at the University of Kentucky (UK), led by Jill Kolesar, Director of the Precision Medicine Center, Co-Chair of the UK Markey Molecular Tumor Board Cancer Center and Professor, UK College of Pharmacy and Dr Vivek Rangnekar, Markey Cancer Center, UK Associate Director and Founding Chairman of the Global Cancer Consortium. The article included a multidisciplinary team of oncologists, researchers, clinical pharmacists and basic scientists from MAHE. The study was also facilitated by the Global Cancer Consortium, which was formed in 2020. The consortium aims to promote partnerships in global cancer research, education and awareness activities.
Speaking about this collaborative study facilitated by the Global Cancer Consortium Lt Gen (Dr) MD Venkatesh, Vice-Chancellor, MAHE said: “The Global Cancer Consortium has launched cutting-edge, cross-national collaborative research to develop next-generation scientists and promote cancer healthcare and has produced several high-quality joint research publications.We are delighted with the contribution of Dr. Rao and his team to cancer research and wish them the best for their future endeavours.
Dr Rao said: “Liquid biopsies obtained from a blood test offer additional benefits such as detection of genes responsible for cancer susceptibility and drug metabolism, minimally invasive and reduced procedural complications, allow for dynamic monitoring of lung cancer treatment resistance and efficacy. Integrating liquid biopsy into cancer care and research enables improved personalized cancer care by selecting the right drug at precise doses, identifying the genomic landscape at the population level, developing new drug molecules and reducing the financial burden for cancer patients.